. Author manuscript; available in PMC: 2016 Dec 1.

Published in final edited form as: Food Chem Toxicol. 2015 Sep 30;86:104–115. doi: 10.1016/j.fct.2015.09.017

Table 4.

Incidence of non-neoplastic lesions in male and female F344/N rats administered 0, 0.0875, 0.175, 0.35, or 0.70 mM glycidamide in the drinking water for two years^a.

Non-neoplastic lesion	Sex	Glycidamide (mM)
Non-neoplastic lesion	Sex	0	0.0875	0.175	0.35	0.70
Brain gliosis	Male	0/48 (0%)^**	1/48 (2%)	0/48 (0%)	0/47 (0%)	4/48 (8%)^*
Brain gliosis	Female	0/48 (0%)^**	0/48 (0%)	4/48 (8%)^*	4/48 (8%)^*	4/48 (8%)^*
Liver hepatocyte degeneration	Male	2/47 (4%)^**	6/47 (13%)	6/48 (13%)	10/47 (21%)^**	8/47 (17%)^**
Liver necrosis	Male	1/47 (2%)^*	5/47 (11%)	2/48 (4%)	7/47 (15%)^*	5/47 (11%)^*
Spinal cord (lumbar) axonal degeneration	Female	5/48 (10%)^*	6/48 (13%)	5/47 (11%)	6/48 (13%)	9/48 (19%)^*
Uterus endometrium cystic hyperplasia	Female	11/48 (23%)^***	17/48 (35%)	14/48 (29%)	14/48 (29%)	23/48 (48%)^***

The data are reported as the number of animals with a non-neoplastic lesion per number of animals examined microscopically and (in parentheses) the % incidence. Statistical analyses for dose-related trends and differences in incidence were conducted by survival-adjusted Poly-3 tests.

An asterisk (*) associated with the 0 mM glycidamide incidence indicates a significant (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) dose-related trend with respect to glycidamide. An asterisk (*) associated with a specific treatment indicates a significant (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) difference compared to the 0 mM glycidamide incidence.